NL8002073A - Nieuwe 16-methoxy-16-methylprostaglandine e1 derivaten, werkwijze voor het bereiden daarvan en hun gebruik als gastroprotectieve middelen. - Google Patents

Nieuwe 16-methoxy-16-methylprostaglandine e1 derivaten, werkwijze voor het bereiden daarvan en hun gebruik als gastroprotectieve middelen. Download PDF

Info

Publication number: NL8002073A
Authority: NL; Netherlands
Prior art keywords: formula; compound; group; hydroxyl; methoxy
Prior art date: 1979-04-10

Application number

NL8002073A

Other languages

English (en)

Dutch (nl)

Original Assignee

Lepetit Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-04-10

Filing date

1980-04-09

Publication date

1980-10-14

1980-04-09 Application filed by Lepetit Spa filed Critical Lepetit Spa

1980-10-14 Publication of NL8002073A publication Critical patent/NL8002073A/nl

Links

238000000034 method Methods 0.000 title claims description 14
230000002178 gastroprotective effect Effects 0.000 title description 4
238000002360 preparation method Methods 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 58
239000000203 mixture Substances 0.000 claims description 29
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
125000006239 protecting group Chemical group 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 8
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
230000009467 reduction Effects 0.000 claims description 7
230000008569 process Effects 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 claims description 3
210000001156 gastric mucosa Anatomy 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
150000001768 cations Chemical class 0.000 claims description 2
ZKCZXVODRKOWIY-UHFFFAOYSA-N diphenylstannane Chemical compound C=1C=CC=CC=1[SnH2]C1=CC=CC=C1 ZKCZXVODRKOWIY-UHFFFAOYSA-N 0.000 claims description 2
230000007062 hydrolysis Effects 0.000 claims description 2
238000006460 hydrolysis reaction Methods 0.000 claims description 2
229910052744 lithium Inorganic materials 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
230000003287 optical effect Effects 0.000 claims description 2
230000002633 protecting effect Effects 0.000 claims description 2
239000003223 protective agent Substances 0.000 claims description 2
229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
239000012279 sodium borohydride Substances 0.000 claims description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229910052987 metal hydride Inorganic materials 0.000 claims 1
150000004681 metal hydrides Chemical class 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
229910052725 zinc Inorganic materials 0.000 claims 1
239000011701 zinc Substances 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 26
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
210000002784 stomach Anatomy 0.000 description 20
208000025865 Ulcer Diseases 0.000 description 18
239000000243 solution Substances 0.000 description 17
239000000047 product Substances 0.000 description 16
229960001340 histamine Drugs 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 12
210000004051 gastric juice Anatomy 0.000 description 11
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
230000036269 ulceration Effects 0.000 description 10
230000028327 secretion Effects 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
238000010898 silica gel chromatography Methods 0.000 description 7
231100000397 ulcer Toxicity 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
229920006395 saturated elastomer Polymers 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
239000003208 petroleum Substances 0.000 description 5
150000003180 prostaglandins Chemical class 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
-1 cyclopentane aldehydes Chemical class 0.000 description 4
230000001120 cytoprotective effect Effects 0.000 description 4
230000027119 gastric acid secretion Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
229940094443 oxytocics prostaglandins Drugs 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000009858 acid secretion Effects 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000002997 prostaglandinlike Effects 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
IWTGMVSCEOXQTC-UHFFFAOYSA-N 2-methoxy-2-methylhexanoic acid Chemical compound CCCCC(C)(OC)C(O)=O IWTGMVSCEOXQTC-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
239000012027 Collins reagent Substances 0.000 description 2
206010065713 Gastric Fistula Diseases 0.000 description 2
206010020601 Hyperchlorhydria Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
FYVPDEYKPSPHFX-PMACEKPBSA-N (1s,2s)-1-hept-6-enyl-2-octylcyclopentane Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCC=C FYVPDEYKPSPHFX-PMACEKPBSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 description 1
KRISPYQCCVEVFA-UHFFFAOYSA-N 3-methoxy-3-methylpentane Chemical compound CCC(C)(CC)OC KRISPYQCCVEVFA-UHFFFAOYSA-N 0.000 description 1
244000171897 Acacia nilotica subsp nilotica Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
239000004015 abortifacient agent Substances 0.000 description 1
231100000641 abortifacient agent Toxicity 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001262 anti-secretory effect Effects 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
LZLOFGMGFADIKQ-UHFFFAOYSA-N benzene;1,4-dioxane Chemical compound C1COCCO1.C1=CC=CC=C1 LZLOFGMGFADIKQ-UHFFFAOYSA-N 0.000 description 1
229960003328 benzoyl peroxide Drugs 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229910000423 chromium oxide Inorganic materials 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
108010041382 compound 20 Proteins 0.000 description 1
238000001816 cooling Methods 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
HXFJIYBRBBJDFC-UHFFFAOYSA-N ethoxyethane;rhodium Chemical compound [Rh].CCOCC HXFJIYBRBBJDFC-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000005445 natural material Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
150000003018 phosphorus compounds Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000000580 secretagogue effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000001562 ulcerogenic effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NL8002073A 1979-04-10 1980-04-09 Nieuwe 16-methoxy-16-methylprostaglandine e1 derivaten, werkwijze voor het bereiden daarvan en hun gebruik als gastroprotectieve middelen. NL8002073A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT21707/79A IT1162731B (it)	1979-04-10	1979-04-10	16-metil-16-metossi-5,6-diidro-prosta-glandine della serie e1 ad attivita'antisecretoria
IT2170779		1979-04-10

Publications (1)

Publication Number	Publication Date
NL8002073A true NL8002073A (nl)	1980-10-14

Family

ID=11185708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8002073A NL8002073A (nl)	1979-04-10	1980-04-09	Nieuwe 16-methoxy-16-methylprostaglandine e1 derivaten, werkwijze voor het bereiden daarvan en hun gebruik als gastroprotectieve middelen.

Country Status (22)

Country	Link
US (1)	US4547521A (da)
JP (1)	JPS55149246A (da)
AT (1)	AT370725B (da)
AU (1)	AU534150B2 (da)
BE (1)	BE882734A (da)
CA (1)	CA1186305A (da)
CH (1)	CH647503A5 (da)
DE (1)	DE3012306A1 (da)
DK (1)	DK155937C (da)
FR (2)	FR2453850B1 (da)
GB (1)	GB2046750B (da)
HK (1)	HK66283A (da)
IE (1)	IE49675B1 (da)
IT (1)	IT1162731B (da)
MX (1)	MX6595E (da)
MY (1)	MY8400336A (da)
NL (1)	NL8002073A (da)
NO (1)	NO151363C (da)
NZ (1)	NZ193370A (da)
SE (1)	SE465126B (da)
SG (1)	SG44483G (da)
ZA (1)	ZA801822B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1190400B (it) *	1985-10-04	1988-02-16	Istituto Biochimico Italiano	Derivati dell'acido 19,20-bis,nor-prostanoico ad attivita' antiulcera e anoressivca,procedimento per la loro preparazione e composizioni farmaceutiche
DE3876230T2 (de) *	1988-01-28	1993-05-06	Merrell Dow Pharma	Verfahren und zwischenprodukte.
EP1085012B1 (en) *	1998-06-04	2008-10-29	Asahi Glass Co., Ltd.	Process for producing a purified prostaglandin derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1495152A (en) *	1974-08-16	1977-12-14	Ici Ltd	Prostanoic acid derivatives
GB1538871A (en) *	1975-01-24	1979-01-24	Lepetit Spa	Prostaglandins
US4064350A (en) *	1976-11-22	1977-12-20	G. D. Searle & Co.	15,16-Dihydroxyprostaglandins

1979
- 1979-04-10 IT IT21707/79A patent/IT1162731B/it active
1980
- 1980-03-18 AU AU56560/80A patent/AU534150B2/en not_active Ceased
- 1980-03-27 ZA ZA00801822A patent/ZA801822B/xx unknown
- 1980-03-29 DE DE19803012306 patent/DE3012306A1/de active Granted
- 1980-04-03 GB GB8011337A patent/GB2046750B/en not_active Expired
- 1980-04-08 NO NO800998A patent/NO151363C/no unknown
- 1980-04-09 MX MX808750U patent/MX6595E/es unknown
- 1980-04-09 CA CA000349411A patent/CA1186305A/en not_active Expired
- 1980-04-09 AT AT0192680A patent/AT370725B/de not_active IP Right Cessation
- 1980-04-09 CH CH2729/80A patent/CH647503A5/fr not_active IP Right Cessation
- 1980-04-09 DK DK151480A patent/DK155937C/da not_active IP Right Cessation
- 1980-04-09 NZ NZ193370A patent/NZ193370A/en unknown
- 1980-04-09 SE SE8002689A patent/SE465126B/sv not_active IP Right Cessation
- 1980-04-09 NL NL8002073A patent/NL8002073A/nl unknown
- 1980-04-09 IE IE723/80A patent/IE49675B1/en not_active IP Right Cessation
- 1980-04-09 JP JP4575980A patent/JPS55149246A/ja active Granted
- 1980-04-10 BE BE0/200185A patent/BE882734A/fr not_active IP Right Cessation
- 1980-04-10 FR FR8008090A patent/FR2453850B1/fr not_active Expired
1982
- 1982-08-03 FR FR8213561A patent/FR2510567B1/fr not_active Expired
1983
- 1983-07-30 SG SG44483A patent/SG44483G/en unknown
- 1983-11-18 US US06/553,470 patent/US4547521A/en not_active Expired - Fee Related
- 1983-12-15 HK HK662/83A patent/HK66283A/xx not_active IP Right Cessation
1984
- 1984-12-30 MY MY336/84A patent/MY8400336A/xx unknown

Also Published As

Publication number	Publication date
IT7921707A0 (it)	1979-04-10
DE3012306A1 (de)	1980-10-23
SG44483G (en)	1984-02-17
NO151363B (no)	1984-12-17
IT1162731B (it)	1987-04-01
JPS55149246A (en)	1980-11-20
IE800723L (en)	1980-10-10
DK155937C (da)	1989-10-16
GB2046750B (en)	1983-04-20
HK66283A (en)	1983-12-23
SE465126B (sv)	1991-07-29
DK155937B (da)	1989-06-05
NO800998L (no)	1980-10-13
BE882734A (fr)	1980-10-10
JPH0141625B2 (da)	1989-09-06
MX6595E (es)	1985-08-14
CA1186305A (en)	1985-04-30
FR2453850B1 (fr)	1985-11-22
FR2510567A1 (fr)	1983-02-04
AT370725B (de)	1983-04-25
AU5656080A (en)	1980-10-16
US4547521A (en)	1985-10-15
NZ193370A (en)	1984-08-24
ATA192680A (de)	1982-09-15
CH647503A5 (fr)	1985-01-31
MY8400336A (en)	1984-12-31
DE3012306C2 (da)	1990-03-22
ZA801822B (en)	1981-03-25
NO151363C (no)	1985-03-27
SE8002689L (sv)	1980-10-11
IE49675B1 (en)	1985-11-27
GB2046750A (en)	1980-11-19
FR2453850A1 (fr)	1980-11-07
FR2510567B1 (fr)	1985-09-06
AU534150B2 (en)	1984-01-05
DK151480A (da)	1980-10-11

Publication	Publication Date	Title
US4024179A (en)	1977-05-17	Substituted ω-pentanorprostaglandins
EP0215860B1 (de)	1989-09-13	9-halogenprostaglandine, verfahren zu ihrer herstellung
US4544764A (en)	1985-10-01	Interphenylene carbacyclin compound
US4132847A (en)	1979-01-02	4-Pyrone prostaglandin antagonists
DK163579B (da)	1992-03-16	Analogifremgangsmaade til fremstilling af carbacyklinderivater
JPH06502390A (ja)	1994-03-17	シクロペンタン誘導体、その製法及びその薬剤学的使用
CH619691A5 (da)	1980-10-15
US4219483A (en)	1980-08-26	4-Pyrone prostaglandin antagonists
NL8002073A (nl)	1980-10-14	Nieuwe 16-methoxy-16-methylprostaglandine e1 derivaten, werkwijze voor het bereiden daarvan en hun gebruik als gastroprotectieve middelen.
FI70009B (fi)	1986-01-31	Foerfarande foer framstaellning av nya 1,5-disubstituerad-2-pyrrolidonfoereningar vilka har prostaglandinliknande biologiska egenskaper
DE2610503C2 (de)	1986-09-18	Optisch aktive 13,14-Dehydro-11- desoxy-prostaglandine, Verfahren zu ihrer Herstellung und sie enthaltendes pharmazeutisches Mittel
JPS61227544A (ja)	1986-10-09	新規［４．２．０］ビシクロオクタン誘導体
FR2515642A1 (fr)	1983-05-06	Nouvelles (11r)-11-deoxy-11-alkyl-6-oxo-prostaglandines et compositions pharmaceutiques les contenant
CA1186306A (en)	1985-04-30	Optically active 16-methoxy-16-methyl-prostaglandin e derivatives and a process for preparing them
US4404372A (en)	1983-09-13	15-Substituted-ω-pentanorprostaglandin derivatives
DE2606051A1 (de)	1976-09-02	2,2-difluor-prostaglandin-e, -f tief alpha, -f tief beta, -a und -b-analoga und verfahren zu deren herstellung
US4547516A (en)	1985-10-15	Antisecretory agents derived from meldrum's acid
DE3204443A1 (de)	1983-08-18	Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FI69062C (fi)	1985-12-10	Nya 16-metoxi-16-metyl-prostaglandin-e1-derivat en metod foer deras framstaellning och deras anvaendning som magen skyddande aemnen
HU184831B (en)	1984-10-29	Process for producing 16-methoxy-16-methyl-prostaglandin-e-1 down derivatives
HU192316B (en)	1987-05-28	Process for producing new carbacyclin derivatives and pharmaceutical compositions containing them
DK155934B (da)	1989-06-05	Analogifremgangsmaade til fremstilling af cis-bicyclo-oe3.3.0aaoctanderivater
US4342868A (en)	1982-08-03	2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(2-furyl)-ω-trisnorprostaglandin E2
US4244887A (en)	1981-01-13	Substituted ω-pentanorprostaglandins
LU82829A1 (fr)	1981-06-04	Nouveaux derives de 16-methoxy-16-methyl-prostaglandine e1,leur procede de preparation et leur utilisation comme agents gastroprotecteurs